INT351318

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.01
First Reported 2010
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 1
Total Number 1
Disease Relevance 0.28
Pain Relevance 0.22

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

oxidoreductase activity (CYP2C19, Cyp1a2) endoplasmic reticulum (CYP2C19, Cyp1a2) enzyme binding (CYP2C19, Cyp1a2)
small molecule metabolic process (CYP2C19) response to stress (Cyp1a2)
CYP2C19 (Homo sapiens)
Cyp1a2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Duloxetine 10 95.76 Very High Very High Very High
sNRI 6 67.56 Quite High
Fibrositis 100 65.60 Quite High
Serotonin 10 42.96 Quite Low
alcohol 3 32.40 Quite Low
Analgesic 5 21.68 Low Low
sSRI 3 16.16 Low Low
central pain 1 15.04 Low Low
Pain 36 10.40 Low Low
analgesia 1 8.56 Low Low
Disease Link Frequency Relevance Heat
Hepatic Insufficiency 2 76.88 Quite High
Fibromyalgia 100 65.60 Quite High
Injury 1 61.28 Quite High
Liver Disease 2 45.76 Quite Low
Renal Insufficiency 1 22.64 Low Low
Disorders Of Creatine Metabolism 3 20.48 Low Low
Pain 42 15.04 Low Low
Fatigue 15 5.00 Very Low Very Low Very Low
Cognitive Disorder 13 5.00 Very Low Very Low Very Low
Depression 12 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The interaction between milnacipran and the cytochrome P450 (CYP) isoenzymes is limited, with no interaction with CYP2D6 or CYP2C19 pathways and minimal interaction with CYP1A2, CYP2C19, CYP2D6 and CYP3A4.
CYP2C19 Neg (no) Binding (interaction) of CYP1A2
1) Confidence 0.01 Published 2010 Journal Journal of pain research Section Body Doc Link PMC3004654 Disease Relevance 0.28 Pain Relevance 0.22

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox